https://scholars.lib.ntu.edu.tw/handle/123456789/633599
Title: | Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study | Authors: | YI-HSIN LIANG KUO-HSING CHEN YU-YUN SHAO |
Keywords: | EGFR; bevacizumab; cetuximab; metastatic colorectal cancer; panitumumab; secondary surgery | Issue Date: | 16-Jun-2023 | Source: | Cancer medicine | Abstract: | The first-line systemic therapy for metastatic colorectal cancer (mCRC) is a combination of one targeted therapy agent and a chemotherapy doublet. Whether bevacizumab or anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (mAb) is the more effective addition to a chemotherapy doublet as the first-line treatment for inoperable KRAS wild-type mCRC remains controversial in prior clinical trials. Moreover, the association between the sidedness of primary tumors and the efficacy of anti-EGFR mAb needs to be addressed. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/633599 | ISSN: | 2045-7634 | DOI: | 10.1002/cam4.6196 |
Appears in Collections: | 腫瘤醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.